World News
Novartis CEO Says US China Biotech Curbs Risk Drug Development
Key Points
Novartis CEO Says US China Biotech Curbs Risk Drug Development Novartis AG Chief Executive Officer Vas Narasimhan said proposed US restrictions on biotech investments in China could hamper the development of new medicines. “The current approach would limit our ability to bring these technologies into our US factories for US patients and vice versa, US into China,” Narasimhan told Bloomberg TV on Friday. “I am hoping more sensible approaches will come out of these discussions.”
Novartis CEO Says US China Biotech Curbs Risk Drug Development
Novartis AG Chief Executive Officer Vas Narasimhan said proposed US restrictions on biotech investments in China could hamper the development of new medicines.
“The current approach would limit our ability to bring these technologies into our US factories for US patients and vice versa, US into China,” Narasimhan told Bloomberg TV on Friday. “I am hoping more sensible approaches will come out of these discussions.”